Immunovant, Inc. (IMVT)
Nasdaq · Healthcare · Biotechnology
$33.25−1.10%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $6.9B
- 52-week range
- $15.95 – $45.42
- 52-week change
- +103.14%
- EPS (trailing)
- −$2.82
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 9, 2026
Fiscal year to Mar 2026
- Net income
- −$506M
- Diluted EPS
- −$2.77
- Free cash flow
- −$407M
From the company’s annual report on SEC EDGAR.
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Headquarters: Durham, United States · 315 employees · immunovant.com